Baseline characteristics of patients according to molecular failure
| . | All cohort (N = 79) . | Molecular relapse (n = 43) . | Molecular persistence (n = 27) . | Molecular progression (n = 9) . | P value . |
|---|---|---|---|---|---|
| Age, median (range), y | 62 (18-81) | 66 (18-81) | 62 (31-77) | 59 (30-70) | ns |
| Male, n (%) | 42 (53) | 24 (56) | 12 (44) | 6 (67) | ns |
| AML type, n (%) | |||||
| De novo | 73 (92) | 36 (84) | 27 (100) | 9 (100) | ns |
| Mutated FLT3-ITD | 22 (28) | 9 (21) | 9 (33) | 4 (67) | ns |
| Previous allogeneic HSCT, n (%) | 7 (9) | 5 (12) | 0 (0) | 2 (22) | <.01 |
| Time from diagnosis to MRD relapse, median (range), mo | 11 (1-98) | 14 (5-98) | 4 (1-18) | 11 (6-16) | ns |
| Venetoclax dose (mg), median (range) | 100 (70-600) | 100 (70-400) | 100 (100-400) | 100 (100-600) | ns |
| MRD at relapse (NPM1 copies/105 ABL), median (range) | 378 (0.27-1 410 000) | 495 (0.27-1 410 000) | 150 (4-10 900) | 9 000 (4-1 080 000) | <.01 |
| Venetoclax combination, n (%) | |||||
| AZA | 44 (56) | 25 (58) | 15 (56) | 4 (44) | ns |
| LDAC | 34 (43) | 17 (40) | 12 (44) | 5 (56) | |
| DEC | 1 (1) | 1 (2) | 0 (0) | 0 (0) | |
| Antifungal prophylaxis∗, n (%) | 53 (67) | 30 (70) | 16 (59) | 7 (78) | ns |
| Number of cycles, median (range) | 3 (1-25) | 4 (1-23) | 2 (1-25) | 2 (1-14) | ns |
| Time between cycles, median (range), d | 33 (19-69) | 35 (19-62) | 33 (27-69) | 29 (26-32) | ns |
| Response | |||||
| MRD negativity, n (%) | 56 (70.9) | 34 (79.1) | 17 (63) | 5 (55.6) | ns |
| MRD reduction, n (%) | 10 (12.7) | 5 (11.6) | 4 (14.8) | 1 (11.1) | ns |
| No response, n (%) | 13 (16.5) | 4 (9.3) | 6 (22.2) | 3 (33.3) | ns |
| ORR (MRD negativity or reduction), n (%) | 66 (83.5) | 39 (90.7) | 21 (77.8) | 6 (66.7) | |
| Time to best MRD response, days, median (range) | 56 (14-724) | 54 (14-389) | 77 (16-724) | 47 (31-83) | <.01 |
| Received HSCT, n (%) | 44 (56) | 28 (65) | 12 (44) | 4 (44) | ns |
| MRD negative before HSCT, n (%) | 25 (32) | 18 (42) | 5 (15) | 2 (22) | ns |
| . | All cohort (N = 79) . | Molecular relapse (n = 43) . | Molecular persistence (n = 27) . | Molecular progression (n = 9) . | P value . |
|---|---|---|---|---|---|
| Age, median (range), y | 62 (18-81) | 66 (18-81) | 62 (31-77) | 59 (30-70) | ns |
| Male, n (%) | 42 (53) | 24 (56) | 12 (44) | 6 (67) | ns |
| AML type, n (%) | |||||
| De novo | 73 (92) | 36 (84) | 27 (100) | 9 (100) | ns |
| Mutated FLT3-ITD | 22 (28) | 9 (21) | 9 (33) | 4 (67) | ns |
| Previous allogeneic HSCT, n (%) | 7 (9) | 5 (12) | 0 (0) | 2 (22) | <.01 |
| Time from diagnosis to MRD relapse, median (range), mo | 11 (1-98) | 14 (5-98) | 4 (1-18) | 11 (6-16) | ns |
| Venetoclax dose (mg), median (range) | 100 (70-600) | 100 (70-400) | 100 (100-400) | 100 (100-600) | ns |
| MRD at relapse (NPM1 copies/105 ABL), median (range) | 378 (0.27-1 410 000) | 495 (0.27-1 410 000) | 150 (4-10 900) | 9 000 (4-1 080 000) | <.01 |
| Venetoclax combination, n (%) | |||||
| AZA | 44 (56) | 25 (58) | 15 (56) | 4 (44) | ns |
| LDAC | 34 (43) | 17 (40) | 12 (44) | 5 (56) | |
| DEC | 1 (1) | 1 (2) | 0 (0) | 0 (0) | |
| Antifungal prophylaxis∗, n (%) | 53 (67) | 30 (70) | 16 (59) | 7 (78) | ns |
| Number of cycles, median (range) | 3 (1-25) | 4 (1-23) | 2 (1-25) | 2 (1-14) | ns |
| Time between cycles, median (range), d | 33 (19-69) | 35 (19-62) | 33 (27-69) | 29 (26-32) | ns |
| Response | |||||
| MRD negativity, n (%) | 56 (70.9) | 34 (79.1) | 17 (63) | 5 (55.6) | ns |
| MRD reduction, n (%) | 10 (12.7) | 5 (11.6) | 4 (14.8) | 1 (11.1) | ns |
| No response, n (%) | 13 (16.5) | 4 (9.3) | 6 (22.2) | 3 (33.3) | ns |
| ORR (MRD negativity or reduction), n (%) | 66 (83.5) | 39 (90.7) | 21 (77.8) | 6 (66.7) | |
| Time to best MRD response, days, median (range) | 56 (14-724) | 54 (14-389) | 77 (16-724) | 47 (31-83) | <.01 |
| Received HSCT, n (%) | 44 (56) | 28 (65) | 12 (44) | 4 (44) | ns |
| MRD negative before HSCT, n (%) | 25 (32) | 18 (42) | 5 (15) | 2 (22) | ns |
AZA, azacitidine; DEC, decitabine; ns, not significant; ORR, overall response rate.
Posaconazole, voriconazole, isavuconazole, and fluconazole were used as antifungal prophylaxis according to each center policy.